Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Yahoo Finance

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox  Yahoo Finance

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Yahoo Finance

Click here to get full coverage on Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan

Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape  Stock Titan

Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan

Click here to get full coverage on NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks  Proactive financial news

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news

Click here to get full coverage on Is nnvc a good buy - AInvest

Is nnvc a good buy - AInvest

Click here to get full coverage on Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan

Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X  Stock Titan

Breakthrough Measles Drug Enters Critical Testing Phase as Global Cases Surge 10X - Stock Titan

Click here to get full coverage on NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz

NanoViricides Inc (NNVC) Quarterly 10-Q Report  Quartz

NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz

Click here to get full coverage on NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case - The Globe and Mail

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case  The Globe and Mail

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case - The Globe and Mail

Click here to get full coverage on NanoViricides: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle

NanoViricides: Fiscal Q3 Earnings Snapshot  San Francisco Chronicle

NanoViricides: Fiscal Q3 Earnings Snapshot - San Francisco Chronicle

Click here to get full coverage on NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Yahoo Finance

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy  Yahoo Finance

NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Yahoo Finance

Click here to get full coverage on NanoViricides nears completion of clinical trial design for MPox treatment - Proactive Investors

NanoViricides nears completion of clinical trial design for MPox treatment  Proactive Investors

NanoViricides nears completion of clinical trial design for MPox treatment - Proactive Investors

Click here to get full coverage on NanoViricides measles drug development animal study imminent - MSN

NanoViricides measles drug development animal study imminent  MSN

NanoViricides measles drug development animal study imminent - MSN

Click here to get full coverage on NanoViricides: Fiscal Q3 Earnings Snapshot - MarketScreener

NanoViricides: Fiscal Q3 Earnings Snapshot  MarketScreener

NanoViricides: Fiscal Q3 Earnings Snapshot - MarketScreener

Click here to get full coverage on NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news

NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak  Proactive financial news

NanoViricides' NV-387 could provide a crucial missing weapon in the fight against US measles outbreak - Proactive financial news

Click here to get full coverage on NanoViricides Eyes $150M+ Government Contract as MPox Drug Enters Phase II Following Rival Drug Failures - Stock Titan

NanoViricides Eyes $150M+ Government Contract as MPox Drug Enters Phase II Following Rival Drug Failures  Stock Titan

NanoViricides Eyes $150M+ Government Contract as MPox Drug Enters Phase II Following Rival Drug Failures - Stock Titan

Click here to get full coverage on NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox - Proactive Investors

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox  Proactive Investors

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox - Proactive Investors

Click here to get full coverage on NanoViricides advances measles drug development amid rising US cases - Proactive financial news

NanoViricides advances measles drug development amid rising US cases  Proactive financial news

NanoViricides advances measles drug development amid rising US cases - Proactive financial news

Click here to get full coverage on NanoViricides: MPox ethics approval enables Phase 2 application - Preview | NYSE-A:NNVC - Proactive Investors

NanoViricides: MPox ethics approval enables Phase 2 application - Preview | NYSE-A:NNVC  Proactive Investors

NanoViricides: MPox ethics approval enables Phase 2 application - Preview | NYSE-A:NNVC - Proactive Investors

Click here to get full coverage on NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news

NanoViricides progresses antiviral portfolio as measles and MPox threats rise  Proactive financial news

NanoViricides progresses antiviral portfolio as measles and MPox threats rise - Proactive financial news

Click here to get full coverage on NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive Investors

NanoViricides touts antiviral NV-387 as tool against new COVID variant  Proactive Investors

NanoViricides touts antiviral NV-387 as tool against new COVID variant - Proactive Investors

Click here to get full coverage on NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors

NanoViricides taps clinical research organization for Phase II trial of NV-387  Proactive Investors

NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors

Click here to get full coverage on NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Cincinnati Enquirer

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025  Cincinnati Enquirer

NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 - Cincinnati Enquirer

Click here to get full coverage on New research warns measles could become endemic again in the US as vaccination rates fall - Proactive Investors

New research warns measles could become endemic again in the US as vaccination rates fall  Proactive Investors

New research warns measles could become endemic again in the US as vaccination rates fall - Proactive Investors

Click here to get full coverage on NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387 | NYSE-A:NNVC - Proactive Investors

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387 | NYSE-A:NNVC  Proactive Investors

NanoViricides prepares for Phase II trial of broad-spectrum antiviral NV-387 | NYSE-A:NNVC - Proactive Investors

Click here to get full coverage on 3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire - Yahoo Finance

3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire  Yahoo Finance

3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire - Yahoo Finance

Click here to get full coverage on NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun - Yahoo Finance

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun  Yahoo Finance

NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun - Yahoo Finance

Click here to get full coverage on NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon  Charlotte Observer

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon - Charlotte Observer

Click here to get full coverage on Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides - Worcester Telegram

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides  Worcester Telegram

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides - Worcester Telegram

Click here to get full coverage on There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate - Worcester Telegram

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate  Worcester Telegram

There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate - Worcester Telegram

Click here to get full coverage on NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial | NYSE-A:NNVC - Proactive Investors

NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial | NYSE-A:NNVC  Proactive Investors

NanoViricides hails broad potential of lead antiviral drug as it prepares to begin first Phase II trial | NYSE-A:NNVC - Proactive Investors

Click here to get full coverage on NanoViricides: A History Of Producing Headlines Without Producing A Product (NYSE:NNVC) - Seeking Alpha

NanoViricides: A History Of Producing Headlines Without Producing A Product (NYSE:NNVC)  Seeking Alpha

NanoViricides: A History Of Producing Headlines Without Producing A Product (NYSE:NNVC) - Seeking Alpha

Click here to get full coverage on Playing the Bird Flu Trade: CVAC BIXT NNVC GOVX DYAI NVAX - Insider Financial

Playing the Bird Flu Trade: CVAC BIXT NNVC GOVX DYAI NVAX  Insider Financial

Playing the Bird Flu Trade: CVAC BIXT NNVC GOVX DYAI NVAX - Insider Financial

Click here to get full coverage on NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus - Proactive financial news

NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus  Proactive financial news

NanoViricides updates investors on Phase 1a/1b trial of antiviral drug candidate for coronavirus - Proactive financial news

Click here to get full coverage on Northern Nevada military news briefs - Nevada Appeal

Northern Nevada military news briefs  Nevada Appeal

Northern Nevada military news briefs - Nevada Appeal

Click here to get full coverage on Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - ACCESS Newswire

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo  ACCESS Newswire

Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo - ACCESS Newswire

Click here to get full coverage on Cough sound-based estimation of vital capacity via cough peak flow using artificial neural network analysis - Nature

Cough sound-based estimation of vital capacity via cough peak flow using artificial neural network analysis  Nature

Cough sound-based estimation of vital capacity via cough peak flow using artificial neural network analysis - Nature

Click here to get full coverage on NNVC Stock Price and Chart — AMEX:NNVC - TradingView

NNVC Stock Price and Chart — AMEX:NNVC  TradingView

NNVC Stock Price and Chart — AMEX:NNVC - TradingView

Click here to get full coverage on 7 Best Nanotech Penny Stocks to Invest In - Insider Monkey

7 Best Nanotech Penny Stocks to Invest In  Insider Monkey

7 Best Nanotech Penny Stocks to Invest In - Insider Monkey

Click here to get full coverage on Prediction: These Will Be the 10 Largest Stocks by 2030 - The Motley Fool

Prediction: These Will Be the 10 Largest Stocks by 2030  The Motley Fool

Prediction: These Will Be the 10 Largest Stocks by 2030 - The Motley Fool

Click here to get full coverage on COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All - Benzinga

COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All  Benzinga

COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All - Benzinga

Click here to get full coverage on NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split - PR Newswire

NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split  PR Newswire

NanoViricides, Inc. Announces One-for-Twenty Reverse Stock Split - PR Newswire

Click here to get full coverage on 3 Nanotech Stocks for Big Growth - InvestorPlace

3 Nanotech Stocks for Big Growth  InvestorPlace

3 Nanotech Stocks for Big Growth - InvestorPlace

Click here to get full coverage on When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Top Rated Trade Entries - Newser

When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Top Rated Trade Entries  Newser

When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Top Rated Trade Entries - Newser

Click here to get full coverage on How NNVC stock performs during market volatility - Free Stock Market Trend Analysis - Newser

How NNVC stock performs during market volatility - Free Stock Market Trend Analysis  Newser

How NNVC stock performs during market volatility - Free Stock Market Trend Analysis - Newser

Click here to get full coverage on How NNVC stock performs during market volatility - Portfolio Boosting Stock Alerts - Newser

How NNVC stock performs during market volatility - Portfolio Boosting Stock Alerts  Newser

How NNVC stock performs during market volatility - Portfolio Boosting Stock Alerts - Newser

Click here to get full coverage on What makes NNVC stock price move sharply - 2x Return Forecast - Newser

What makes NNVC stock price move sharply - 2x Return Forecast  Newser

What makes NNVC stock price move sharply - 2x Return Forecast - Newser

Click here to get full coverage on When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Access to Investors Club - Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Access to Investors Club  Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Access to Investors Club - Newser

Click here to get full coverage on When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - High Potential Safe Trades - Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - High Potential Safe Trades  Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - High Potential Safe Trades - Newser

Click here to get full coverage on When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Exclusive Stock Market Insights - Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Exclusive Stock Market Insights  Newser

When ACMR stock expected to show significant growthIs NNVC stock a good long term investment option - Free Exclusive Stock Market Insights - Newser

Click here to get full coverage on When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Free Growth Investment Group - Newser

When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Free Growth Investment Group  Newser

When NNVC stock expected to show significant growthIs PHIO stock a good long term investment option - Free Growth Investment Group - Newser

Click here to get full coverage on How NNVC stock performs during market volatility - Free Smart Money Group - Newser

How NNVC stock performs during market volatility - Free Smart Money Group  Newser

How NNVC stock performs during market volatility - Free Smart Money Group - Newser

Click here to get full coverage on Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC) - Defense World

Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC)  Defense World

Wealth Enhancement Advisory Services LLC Invests $26,000 in NanoViricides, Inc. (NYSE:NNVC) - Defense World

Click here to get full coverage on NanoViricides (NYSE:NNVC) Trading Up 0.7% – Still a Buy? - Defense World

NanoViricides (NYSE:NNVC) Trading Up 0.7% – Still a Buy?  Defense World

NanoViricides (NYSE:NNVC) Trading Up 0.7% – Still a Buy? - Defense World

Click here to get full coverage on NanoViricides (NYSE:NNVC) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head Review - Defense World

NanoViricides (NYSE:NNVC) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head Review  Defense World

NanoViricides (NYSE:NNVC) and Gemini Therapeutics (NASDAQ:GMTX) Head-To-Head Review - Defense World

Click here to get full coverage on How NKSH stock performs during market volatility - Free Stock Market Return Analysis - Newser

How NKSH stock performs during market volatility - Free Stock Market Return Analysis  Newser

NanoViricides Inc (NNVC)

Price Chart

Key Statistics

Technicals

About NNVC

Latest News

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox - Yahoo Finance

Breakthrough MPox Drug NV-387 Targets Deadly Clade I Strain as Phase II Trial Takes Shape - Stock Titan

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks - Proactive financial news

Advanced Charts

Top Gainers

Top Losers